Ranibizumab
Contents
Description
Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat neovascular (wet) age-related macular degeneration and other retinal conditions. The drug works by preventing abnormal blood vessel growth and leakage in the retina.
Indications & Therapeutic Use
neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion
Linked Diseases:
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Ranibizumab — GNH India
36 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | ranibizumab |
| Brands | 1 brand available |
| Active Ingredient | ranibizumab |
| Drug Class | neovascular age-related macular degeneration |
| Manufacturer | Genentech/Novartis |
| Dosage Forms | intravitreal injection, 10 mg/mL solution |
| Medical Code | S01LA04 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00056836 |
| Countries | 9 countries |